- Resource
- Source: Campus Sanofi
- Nov 19, 2025
6 min
Guidelines for RSV prevention with Nirsevimab
Respiratory Syncytial Virus (RSV) is a major cause of lower respiratory tract infections in infants and young children. Nirsevimab is a long-acting monoclonal antibody that provides passive immunization against RSV, offering protection throughout the RSV season with a single dose
MAT-SA-2501077/V1/December 2025